AstraZeneca
11.870,00 GBpVariación respecto al cierre anterior: −1,35 %Variación absoluta: −162,00 GBp
En resumen
- Crecimiento de los ingresos
- +8,63 %
- 2025 frente a 2024
- Crecimiento del beneficio neto
- +45,34 %
- 2025 frente a 2024
- Margen neto
- 17,4 %
- 2024: 13,0 %
Datos financieros
Importes en millones de USD; valores por acción en USD; acciones en millones.
| Partida | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Flujo de caja operativo | 14.575 | 11.861 | 10.345 | 9.808 | 5.963 | 4.799 | 2.969 | 2.618 | 3.578 | 4.145 |
| Amortizaciones | 5.392 | 4.981 | 4.851 | 5.178 | 4.039 | 2.835 | 2.714 | 2.731 | 2.320 | 2.181 |
| Inversiones de capital (capex) | -2.810 | -1.924 | -1.361 | -1.091 | -1.091 | -961 | -979 | -1.043 | -1.326 | -1.446 |
| Flujo de caja de inversión | -6.808 | -7.980 | -4.064 | -2.960 | -11.058 | -285 | -657 | 963 | -2.328 | -3.969 |
| Flujo de caja de financiación | -7.544 | -3.996 | -6.567 | -6.823 | 3.649 | -2.203 | -1.765 | -2.044 | -2.936 | -1.324 |
| Dividendos pagados | -4.846 | -4.606 | -4.491 | -4.364 | -3.856 | -3.572 | -3.592 | -3.484 | -3.519 | -3.561 |
| Recompra de acciones | -521 | -81,0 | — | — | — | — | — | — | — | — |
| Emisión de deuda | 379 | 6.492 | 3.977 | 74,0 | 12.929 | 3.256 | 500 | 2.971 | 2.324 | 2.491 |
| Amortización de deuda | -2.401 | -4.999 | -5.210 | -1.515 | -5.275 | -1.816 | -2.202 | -1.498 | -1.764 | -319 |
| Efecto del tipo de cambio | 46,0 | -93,0 | -60,0 | -80,0 | -62,0 | 12,0 | 5,0 | -38,0 | -66,0 | 21,0 |
| Variación neta de efectivo | 269 | -208 | -346 | -55,0 | -1.508 | 2.323 | 552 | 1.499 | -1.752 | -1.127 |
| Flujo de caja libre | 11.765 | 9.937 | 8.984 | 8.717 | 4.872 | — | — | — | — | — |
| Flujo de caja libre apalancado | 7.865 | 8.461 | 9.040 | 12.485 | -1.845 | 3.441 | 6.213 | 3.698 | 4.195 | 4.476 |